Browse Contents
Special Offers
SCImago Journal Ranking
| Forthcoming Special Issues |
Applications of gold nanoparticles(GNPs) in cancer managementsGuest Editor(s): Ali Yadollahpour Tentative Publication Date: May, 2017 Submit Abstract via Email Download Description |
| Special Issues - In-Press |
| Please visit again after some time to view these Issues. |
| Published Special Issues |
The Use Of Positron Emission Tomography In External Beam Therapy Dose PlanningCurrent Radiopharmaceuticals, Volume 8, Number 1 Guest Editor(s): Kalevi Kairemo |
Current Radiopharmaceuticals
,Volume 11
-Number 3
Biography Open Access
Meet Our Editorial Board Member
Editorial Open Access
The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications
, 11(3): 154 - 155Valery Radchenko, Paul Schaffer and F.F. (Russ) Knapp
DOI: 10.2174/187447101103180911115600
The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications
Review Article Open Access
Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
, 11(3): 156 - 172Andrew Kyle Henderson Robertson, Caterina Fortunata Ramogida, Paul Schaffer and Valery Radchenko*
DOI: 10.2174/1874471011666180416161908
Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
Review Article
The Production of Ac-225
Review Article
NorthStar Perspectives for Actinium-225 Production at Commercial Scale
, 11(3): 180 - 191James T. Harvey*
DOI: 10.2174/1874471011666180515123848
NorthStar Perspectives for Actinium-225 Production at Commercial Scale
Review Article
Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies
, 11(3): 192 - 199Joseph G. Jurcic*
DOI: 10.2174/1874471011666180525102814
Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies
Review Article Open Access
An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
, 11(3): 200 - 208Alfred Morgenstern*, Christos Apostolidis, Clemens Kratochwil, Mike Sathekge, Leszek Krolicki and Frank Bruchertseifer
DOI: 10.2174/1874471011666180502104524
An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
Review Article
Dosimetry and Radiobiology of Alpha-Particle Emitting Radionuclides
, 11(3): 209 - 214George Sgouros*, Robert Hobbs and Anders Josefsson
DOI: 10.2174/1874471011666180426130058
Dosimetry and Radiobiology of Alpha-Particle Emitting Radionuclides
Articles Ahead of Print
Synthesis of [18F]FAZA Using Nosyl and Iodo Precursors for Nucleophilic Radiofluorination
William Sun, Cheryl Falzon, Ebrahim Naimi , Ali Akbari , Leonard I Wiebe*, Manju Tandon and Piyush Kumar
View Abstract View on PubMed
Determination of Gamma Camera’s Calibration Factors for Quantitation of Diagnostic Radionuclides in Simultaneous Scattering and Attenuation Correction
Afrouz Asgari, Mansour Ashoor, Leila Sarkhosh, Abdollah Khorshidi* and Parvaneh Shokrani
View Abstract View on PubMed
Choline-PET/CT in the Differential Diagnosis Between Cystic Glioblastoma and Intraparenchymal Hemorrhage
Pierpaolo Alongi*, Ignazio Gaspare Vetrano, Elisa Fiasconaro, Valerio Alaimo, Riccardo Laudicella, Marina Bellavia, Francesca Rubino, Sergio Bagnato and Giuseppe Galardi
View Abstract View on PubMed
Evaluating the Radioprotective Effect of Curcumin on Rat’s Heart Tissues
Sedighe Kolivand, Peyman Amini, Hana Saffar, Saeed Rezapoor, Elahe Motevaseli*, Masoud Najafi*, Farzad Nouruzi, Dheyauldeen Shabeeb and Ahmed Eleojo Musa
View Abstract View on PubMed
Dosimetry and Toxicity Studies of the Novel Sulfonamide Derivative of Sulforhodamine 101([18F]SRF101) at a Preclinical Level
I Kreimerman, E Mora-Ramirez , A. L Reyes, M Bardies , E Savio * and H Engler
View Abstract
Abstracts Ahead of Print
There are currently no Abstracts Ahead of Print available for this journal.
Editor's Choice
The Production of Ac-225
, 2018; 11(3): 173 - 179Jonathan W. Engle*
DOI: 10.2174/1874471011666180418141357
NorthStar Perspectives for Actinium-225 Production at Commercial Scale
, 2018; 11(3): 180 - 191James T. Harvey*
DOI: 10.2174/1874471011666180515123848
Ga-68 Nanoparticles and Ultra-small Nanoparticle: Next Generation of PET Radiopharmaceuticals?
, 2018; 11(2): 123 - 129Mohammed Al-Qahtani, Yousif Al Malki, Hadeel Mutwali, Edward Helal-Neto and Ralph Santos-Oliveira*
DOI: 10.2174/1874471011666180418110206
Mechanisms of Radiation Bystander and Non-Targeted Effects: Implications to Radiation Carcinogenesis and Radiotherapy
, 2018; 11(1): 34 - 45Rasoul Yahyapour, Elahe Motevaseli, Abolhasan Rezaeyan, Hamid Abdollahi, Bagher Farhood, Mohsen Cheki, Masoud Najafi* and Vilmar Villa
DOI: 10.2174/1874471011666171229123130
Personalized & Precision Medicine in Cancer: A Theranostic Approach
, 2017; 10(3): 166 - 170Partha Choudhury* and Manoj Gupta
DOI: 10.2174/1874471010666170728094008
PET/MR Tomographs: A Review with Technical, Radiochemical and Clinical Perspectives
, 2017; 10(3): 184 - 194Giampiero Giovacchini, Elisabetta Giovannini, Mattia Riondato and Andrea Ciarmiello*
DOI: 10.2174/1874471010666170816125051
β -[18F]Fluoro Azomycin Arabinoside (β -[18F]FAZA): Synthesis, Radiofluorination and Preliminary PET Imaging of Murine A431 Tumors
, 2017; 10(2): 93 - 101Piyush Kumar*, Peter Roselt, Gerald Reischl, Carlene Cullinane, Davood Beiki, Walter Ehrlichmann, David Binns, Ebrahim Naimi, Jennifer Yang, Rodney Hicks, Hans-Juergen Machulla and Leonard I. Wiebe
DOI: 10.2174/1874471010666170313120540
Experiences with 99mTc-HMPAO in a Diagnostic Pathway for Violent Patients with Schizophrenic Spectrum Disorders
, 2017; 10(2): 115 - 122Morten Jacobsen*, Arvid Jensen, Guttorm Breivik Storvestre, Tone Marie Bergstrom, Diyar Nori Mohamad Rashi, Bjorn Nielssen , Pal Wiktor and Knut-Erik Hymer
DOI: 10.2174/1874471010666170621122221
177Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma
, 2017; 10(1): 21 - 28Ximena Camacho, Victoria Calzada, Marcelo Fernandez, Omar Alonso, Roger Chammas, Eloisa Riva, Juan Pablo Gambini and Pablo Cabral
DOI: 10.2174/1874471009666161010155246
Radiolabeled Sugars Used for PET and SPECT Imaging
, 2016; 9(3): 180 - 186Brianda Barrios-Lopez and Kim Bergstrom
DOI: 10.2174/1874471008666150525104725
Open Access Articles
An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
, 2018; 11(3): 200 - 208Alfred Morgenstern*, Christos Apostolidis, Clemens Kratochwil, Mike Sathekge, Leszek Krolicki and Frank Bruchertseifer
Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
, 2018; 11(3): 156 - 172Andrew Kyle Henderson Robertson, Caterina Fortunata Ramogida, Paul Schaffer and Valery Radchenko*
Dosimetry and Toxicity Studies of the Novel Sulfonamide Derivative of Sulforhodamine 101([18F]SRF101) at a Preclinical Level
, 2018; 11: 1 - 9 (E-Pub Ahead of Print)I Kreimerman, E Mora-Ramirez , A. L Reyes, M Bardies , E Savio * and H Engler
Synthesis of [18F]2B-SRF101: A Sulfonamide Derivative of the Fluorescent Dye Sulforhodamine 101
, 2017; 10(3): 212 - 220Ingrid Kreimerman, Williams Porcal, Silvia Olivera, Patricia Oliver, Eduardo Savio* and Henry Engler
Automated One-pot Radiosynthesis of [11C]S-adenosyl Methionine
, 2017; 10(3): 203 - 211Florencia Zoppolo, Williams Porcal, Patricia Oliver, Eduardo Savio* and Henry Engler
Experiences with 99mTc-HMPAO in a Diagnostic Pathway for Violent Patients with Schizophrenic Spectrum Disorders
, 2017; 10(2): 115 - 122Morten Jacobsen*, Arvid Jensen, Guttorm Breivik Storvestre, Tone Marie Bergstrom, Diyar Nori Mohamad Rashi, Bjorn Nielssen , Pal Wiktor and Knut-Erik Hymer
Gallium-68 in Medical Imaging
, 2016; 9(3): 187 - 207Lucia Martiniova, Louis De Palatis, Elba Etchebehere and Gregory Ravizzini
Biodistribution and Dosimetry of 177Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
, 2013; 6(1): 20 - 27Ada H. V. Repetto-Llamazares, Roy H. Larsen, Camilla Mollatt, Michael Lassmann and Jostein Dahle
Targeted α-Particle Therapy: A Clinical Overview
, 2008; 1(3): 251 - 253Massimo Salvatori, Luca Indovina and Luigi Mansi
Radium-223: From Radiochemical Development to Clinical Applications in Targeted Cancer Therapy
, 2008; 1(3): 203 - 208Oyvind S. Bruland, Thora J. Jonasdottir, Darrell R. Fisher and Roy H. Larsen
Increased [11C]Choline Uptake in Bronchioloalveolar Cell Carcinoma with Negative [18F]FDG Uptake. A PET/CT and Pathology Study
, 2008; 1(2): 62 - 64Maria Picchio, C. Messa, B. Giglioni, F. Sanvito, E. Caporizzo, C. Landoni, G. Arrigoni, A. Carretta, R. Nicoletti, P. Zannini, A. Del Maschio and F. Fazio
Asymmetric Synthesis of L-[3-13C]Tryptophan
, 2008; 1(2): 122 - 124Kazuhiko Takatori, Myonghui Lee and Masahiro Kajiwara
Synthesis of 1-Amino-2-[3-13C]propanol Hydrochloride: Completion of Synthetic Methods for all of its 13C- and 15N-Isotopomers
, 2008; 1(2): 120 - 121K. Iida, Y. Nakajima and M. Kajiwara
Most Cited Articles
Radioimmunotherapy of Metastatic Prostate Cancer with 177Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody
, 2016; 9(1): 44-53.Shankar Vallabhajosula, Anastasia Nikolopoulou, Yuliya S. Jhanwar, Gurveen Kaur, Scott T. Tagawa, David M. Nanus, Neil H. Bander and Stanley J. Goldsmith
DOI: 10.2174/1874471008666150313114005
Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with 177Lu and Conjugated to Peptides
, 2015; 8(2): 150-159.Guillermina Ferro-Flores, Blanca E. Ocampo-García, Clara L. Santos-Cuevas, Flor de María Ramírez, Erika P. Azorín-Vega and Laura Meléndez-Alafort
DOI: 10.2174/1874471008666150313115423
Evolving Important Role of Lutetium-177 for Therapeutic Nuclear Medicine
, 2015; 8(2): 78-85.Ambikalmajan M.R. Pillai and Furn F. (Russ) Knapp
DOI: 10.2174/1874471008666150312155959
Indirect Production of No Carrier Added (NCA) 177Lu from Irradiation of Enriched 176Yb: Options for Ytterbium/Lutetium Separation
, 2015; 8(2): 107-118.Ashutosh Dash, Rubel Chakravarty, Furn F. (Russ) Knapp and Ambikalmajan M.R. Pillai
DOI: 10.2174/1874471008666150312161942
Editorial (Thematic Issue: Lutetium-177 Labeled Therapeutics: 177Lu-PSMA is Set to Redefine Prostate Cancer Treatment)
, 2016; 9(1): 6-7.Ambikalmajan M.R. Pillai and Furn F. (Russ) Knapp
DOI: 10.2174/187447100901151123124826
Theranostic Applications of Lutetium-177 in Radionuclide Therapy
, 2016; 9(1): 94-101.Tapas Das and Sharmila Banerjee
DOI: 10.2174/1874471008666150313114644
Production of No-Carrier Added Lutetium-177 by Irradiation of Enriched Ytterbium-176
, 2015; 8(2): 95-106.Valery A. Tarasov, Oleg I. Andreev, Evgeny G. Romanov, Rostislav A. Kuznetsov, Vladimir V. Kupriyanov and Ivan V. Tselishchev
DOI: 10.2174/1874471008666150312160855
Overview of Development and Formulation of 177Lu-DOTA-TATE for PRRT
, 2016; 9(1): 8-18.Wouter A.P. Breeman, Ho Sze Chan, Rory M.S. de Zanger, Mark K. Konijnenberg and Erik de Blois
DOI: 10.2174/1874471008666150313111131
Planning of External Beam Radiotherapy for Prostate Cancer Guided by PET/CT
, 2015; 8(1): 19-31.Finn Edler von Eyben, Kalevi Kairemo, Timo Kiljunen and Timo Joensuu
DOI: 10.2174/1874471008666150316222203
Evaluation of a Labelled Bacteriophage with 99mTc as a Potential Agent for Infection Diagnosis
, 2016; 9(2): 137-142.María Elena Cardoso, Leticia Fernández, Emilia Tejería, Patricia Esperón and Mariella Terán
DOI: 10.2174/1874471009666160215162023
Most Accessed Articles
An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
, 2018; 11(3): 200-208.Alfred Morgenstern*, Christos Apostolidis, Clemens Kratochwil, Mike Sathekge, Leszek Krolicki and Frank Bruchertseifer
DOI: 10.2174/1874471011666180502104524
Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma
, 2018; 11(1): 14-21.Natasha Alexander, Reza Vali, Hojjat Ahmadzadehfar, Amer Shammas and Sylvain Baruchel*
DOI: 10.2174/1874471011666171215093112
Mechanisms of Radiation Bystander and Non-Targeted Effects: Implications to Radiation Carcinogenesis and Radiotherapy
, 2018; 11(1): 34-45.Rasoul Yahyapour, Elahe Motevaseli, Abolhasan Rezaeyan, Hamid Abdollahi, Bagher Farhood, Mohsen Cheki, Masoud Najafi* and Vilmar Villa
DOI: 10.2174/1874471011666171229123130
Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
, 2018; 11(3): 156-172.Andrew Kyle Henderson Robertson, Caterina Fortunata Ramogida, Paul Schaffer and Valery Radchenko*
DOI: 10.2174/1874471011666180416161908
PET/CT With 68Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical Implications
, 2018; 11(1): 4-13.Giampiero Giovacchini*, Elisabetta Giovannini, Mattia Riondato and Andrea Ciarmiello
DOI: 10.2174/1874471010666171101121803
Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer–A Single Institution Experience
, 2018; 11(2): 147-152.Kalevi Kairemo, Denai R. Milton, Elba Etchebehere, Eric M. Rohren and Homer A. Macapinlac*
DOI: 10.2174/1874471011666180629145030
Letter to the Editor: International Consensus Radiochemistry Nomenclature Guidelines
, 2018; 11(1): 73-75.Heinz H. Coenen*, Antony D. Gee*, Michael Adam, Gunnar Antoni, Cathy S. Cutler, Yasuhisa Fujibayashi, Jae Min Jeong, Robert H. Mach, Thomas L. Mindt, Victor W. Pike and Albert D. Windhorst
DOI: 10.2174/187447101101180404111248
Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings
, 2018; 11(1): 22-33.Giulia Anna Follacchio*, Maria Silvia De Feo, Giuseppe De Vincentis, Francesco Monteleone and Mauro Liberatore
DOI: 10.2174/1874471011666171211161851
Theranostic Applications of Lutetium-177 in Radionuclide Therapy
, 2016; 9(1): 94-101.Tapas Das and Sharmila Banerjee
DOI: 10.2174/1874471008666150313114644
Webmaster Contact: info@benthamscience.org